Project Grant K99CA307604
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $127K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Utah $183,600 under the Cancer Research Manpower program (CFDA 93.398) to conduct research addressing immunotherapy resistance in cancer patients. The three-year project, initiated September 1, 2025 and concluding August 31, 2028, focuses on reprogramming myeloid cells through JAK (Janus kinase) inhibition to enhance checkpoint blockade therapy efficacy. The research examines the combination of...
- Federal Grant Award Summary The University of Utah received a $634,900 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded April 1, 2026, with completion scheduled for March 31, 2031. This five-year research initiative investigates combined Focal Adhesion Kinase (FAK) inhibition with Mitogen-Activated Protein Kinase (MAPK) blockade as a therapeutic approach for brain metastases arising from cutaneous melanoma. The research...
- Federal Project Grant Award Summary The University of Utah received a $154,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2027. This technology-oriented project will develop and validate a novel genetic mouse model system for pancreatic ductal adenocarcinoma (PDAC) research. The primary deliverable is the creation and functional validation of a "FLP-OUT" mouse model using a...
- Federal Grant Award Summary The National Cancer Institute awarded a $669,949 Project Grant (CFDA 93.396, Cancer Biology Research program) to the University of Utah, effective August 15, 2025, through July 31, 2030, to elucidate the functional role and therapeutic potential of G Protein-Coupled Receptor Kinase 2 (GRK2) in primary and therapy-resistant basal cell carcinoma (BCC). The research addresses a critical therapeutic gap in BCC treatment, where existing Smoothened (SMO) inhibitors lose...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant totaling $648,626 to the University of California, Irvine under the Cancer Treatment Research program (CFDA 93.395) on April 2, 2026, with a completion date of March 31, 2031. This award funds research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically examining how PD-1 (Programmed Death-1) inhibition affects tumor-infiltrating regulatory T cells...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $201,960 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the University of Utah, with performance scheduled from September 11, 2025, through August 31, 2028. This award supports research investigating the immune-mediated mechanisms by which beneficial gut bacteria enhance anti-tumor immunity in colorectal cancer (CRC). The research focuses on characterizing how Bacteroides uniformis, a human gut...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $653,967 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Treatment Research program (CFDA 93.395) on March 16, 2026, with a completion date of February 28, 2031. This research project investigates the mechanistic basis and therapeutic strategies for PPP2R1A mutations in gynecological cancers, specifically uterine serous endometrial carcinoma and ovarian clear cell carcinoma. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year research initiative investigates the molecular mechanisms by which the KEAP1-NRF2 redox-sensing pathway regulates CD8 T cell adaptation to chronic antigen receptor signaling in cancer and chronic infection contexts. The research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Oregon Health & Science University $2,265,578 through the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, to support a four-year research project concluding August 31, 2029. The funded research investigates androgen receptor (AR) signaling in conventional dendritic cells (CDCs) and its relationship to sex-based differences in anti-tumor immune function, with particular focus on melanoma....
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $930,500 under the Cancer Biology Research program (CFDA 93.396) to the University of Arizona, effective September 10, 2025, with a completion date of August 31, 2032. This award supports fundamental research investigating loss of chromosome Y (LOY) in cancer development and progression, with particular focus on bladder cancer as a clinically relevant model. The research aims to advance understanding of how...